• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study
ConclusionA significant proportion of ASA non-responsiveness was recorded regardless of ASA formulation administered. The increased risk of ASA non-responsiveness in diabetic patients needs further exploration by larger prospective studies.
Source: European Journal of Clinical Pharmacology - September 19, 2022 Category: Drugs & Pharmacology Source Type: research

A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulants vs vitamin K antagonists after transcatheter aortic valve replacement in patients with atrial fibrillation
ConclusionWhile the results of this analysis reveal NOAC as a potential alternate treatment modality to VKA in post-TAVR patients with AF, further research is needed to determine the full safety and efficacy profile of NOAC (PROSPERO: CRD42021283548).
Source: European Journal of Clinical Pharmacology - August 9, 2022 Category: Drugs & Pharmacology Source Type: research

Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase
ConclusionsFatal AEs related to rivaroxaban combined with aspirin, including bleeding and ischemic events, have been reported mostly in the elderly, and sometimes involved medication errors. The fatal AEs mainly manifested as serious bleeding, and most of them occurred in patients with concurrent multiple risk factors. Monitoring coagulation during rivaroxaban treatment is recommended in very high-risk ASCVD populations, and attention should be paid to prevention of medication errors.
Source: European Journal of Clinical Pharmacology - July 1, 2022 Category: Drugs & Pharmacology Source Type: research

Feasibility and usability of a mobile health tool on anticoagulation management for patients with atrial fibrillation: a pilot study
ConclusionOverall, the anticoagulation management model developed in this study could be involved in the full process of anticoagulation therapy in AF patients to improve rationality, adherence, and satisfaction in both medical professionals and patients. However, the usability, feasibility, and acceptability of the I-Anticoagulant-based anticoagulation management model need to be further assessed through well-designed random clinical trials.
Source: European Journal of Clinical Pharmacology - October 20, 2021 Category: Drugs & Pharmacology Source Type: research

Utility of a pharmacogenetic-driven algorithm in guiding dual antiplatelet therapy for patients undergoing coronary drug-eluting stent implantation in China
ConclusionTailored DAPT based on the PRiS could assist in improving the prognosis of patients undergoing DES implantation. Further randomized controlled trials are required to provide more evidence for PRiS-guided DAPT.
Source: European Journal of Clinical Pharmacology - October 12, 2021 Category: Drugs & Pharmacology Source Type: research

The efficacy and safety of rivaroxaban in coronary artery disease patients with heart failure and sinus rhythm: a systematic review and meta-analysis
ConclusionsIn SR patients with CAD and HF, the rates of MI and stroke associated with rivaroxaban combined with APT were lower than those associated with APT alone, and the two treatments had similar rates of all-cause death and major bleeding.
Source: European Journal of Clinical Pharmacology - September 21, 2021 Category: Drugs & Pharmacology Source Type: research

Safety and efficacy of new oral anticoagulants compared to those of warfarin in AF patients with cancer: a meta-analysis of randomized clinical trials and observational studies
ConclusionOur meta-analysis confirms that NOACs are as safe and effective as warfarin and can be applied in the real world; this data can serve as a reference for clinical doctors for formulating treatment strategies.
Source: European Journal of Clinical Pharmacology - April 1, 2021 Category: Drugs & Pharmacology Source Type: research

Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF registry sub-cohort analysis
ConclusionsA high trough apixaban level in patients indicated for standard dose was not associated with adverse events, while a high apixaban level in patients indicated for a reduced dose was associated with bleeding requiring hospitalization.
Source: European Journal of Clinical Pharmacology - May 24, 2020 Category: Drugs & Pharmacology Source Type: research

Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication
ConclusionMost of the well-established risk factors were found to be significantly associated with bleeding events in our study. We additionally found that women had a lower incidence of bleeding. Potential biases are selection effects, residual confounding and unmeasured frailty.
Source: European Journal of Clinical Pharmacology - March 27, 2020 Category: Drugs & Pharmacology Source Type: research

Tailored P2Y 12 inhibitor treatment in patients undergoing non-urgent PCI —the POPular Risk Score study
ConclusionSelective intensification of P2Y12 inhibitor treatment after non-urgent PCI based on the POPular Risk Score is associated with a reduction in thrombotic events without an increase in bleeding events.
Source: European Journal of Clinical Pharmacology - June 13, 2019 Category: Drugs & Pharmacology Source Type: research

Pages: 1  2  3